P3 Health Partners (PIII) vs GeneDx (WGS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
P3 Health Partners (PIII) has outperformed GeneDx (WGS) over the past year, losing 40.7% versus a loss of 44.8%. Over five years, WGS leads with a -73.7% price change compared with -98.9% for PIII. GeneDx is the larger company by market cap ($2.02 billion vs $1.05 billion), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PIII | WGS |
|---|---|---|
| Share price | $5.13 | $67.73 |
| Market cap | $1.05B | $2.02B |
| 1-day change | -3.33% | 0.00% |
| YTD return | +52.15% | -47.92% |
| 1-year return | -40.67% | -44.80% |
| 5-year return | -98.93% | -73.65% |
| Forward P/E | — | 56.51 |
| EPS (TTM) | $-33.02 | $-3.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $427.54M |
| Revenue growth (YoY) | — | +39.97% |
| Net income (latest FY) | — | $-21.02M |
| Gross margin | — | 69.74% |
| Operating margin | — | -3.06% |
| Net margin | — | -4.92% |
| 52-week high | $16.89 | $170.87 |
| 52-week low | $1.52 | $32.21 |
| Distance from 52-week high | -69.61% | -60.36% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +250.65% | +38.05% |
| Average volume | 32.48K | 730.21K |
| Shares outstanding | 3.91M | 29.82M |
| Employees | 320 | 1,300 |
| Sector | Health Care | Health Care |
| Industry | Medical/Nursing Services | Medical/Nursing Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About P3 Health Partners
PIII stock →P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers.
Health Care · Medical/Nursing Services · 320 employees
About GeneDx
WGS stock →GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Health Care · Medical/Nursing Services · 1,300 employees
PIII vs WGS FAQ
Which is bigger, P3 Health Partners or GeneDx?
GeneDx (WGS) is larger, with a market capitalization of $2.02B compared with $1.05B for P3 Health Partners (PIII).
Which stock has performed better over the past year, PIII or WGS?
PIII returned -40.67% over the past 12 months, compared with -44.80% for WGS (price return, excluding dividends). Past performance does not predict future results.
Are P3 Health Partners and GeneDx in the same industry?
Yes. Both are classified in the Medical/Nursing Services industry within the Health Care sector.